Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients
Author: Lee, A.
Patterson, K.A.
Tan, D.J.
Wilson, M.E.
Proudman, S.M.
Stevens, W.
Nikpour, M.
Sahhar, J.
Ngian, G.-S.
Roddy, J.
Roberts-Thomson, P.J.
Walker, J.G.
Citation: Scandinavian Journal of Rheumatology, 2021; 50(6):469-474
Publisher: Taylor & Francis
Issue Date: 2021
ISSN: 0300-9742
Statement of
AYS Lee, KA Patterson, DJ Tan, ME Wilson, SM Proudman, W Stevens, M Nikpour, J Sahhar, G-S Ngian, J Roddy, PJ Roberts-Thomson, JG Walker
Abstract: Objective: We undertook a comprehensive cross-sectional analysis of a multicentred Australian cohort of systemic sclerosis (SSc) patients to evaluate the associations of anti-Ro52/TRIM21 with SSc pulmonary involvement. Method: The study included 596 patients from the Australian Scleroderma Cohort Study database whose anti-Ro52/TRIM21 status was known. Anti-Ro52/TRIM21 was measured via line immunoassay. Data on demographic variables, autoantibody profiles, presence of interstitial lung disease (ILD), presence of pulmonary arterial hypertension (PAH), oxygen saturation, Six-Minute Walk Test distance, Borg dyspnoea score, and lung function tests were extracted. SPSS software was used to examine associations using univariate and multivariate analyses. Results: Anti-Ro52/TRIM21 was present in 34.4% of SSc patients. In the cross-sectional analysis, anti-Ro52/TRIM21 was independently associated with PAH [odds ratio 1.75, 95% confidence interval (CI) 1.05–2.90], but not ILD or other surrogate measures of pulmonary involvement such as average patient oxygen saturation. The antibody, however, was also associated with a higher forced vital capacity/diffusing capacity of the lung for carbon monoxide ratio. Prospectively, anti-Ro52/TRIM21 was also associated with an increased risk of death in patients with SSc (hazard ratio 1.62, 95% CI 1.11–2.35), independent of confounding factors. The primary cause of death appeared to be related to PAH and/or ILD, and anti-Ro52/TRIM21 was associated with PAH-related complications. Conclusion: Anti-Ro52/TRIM21 was independently associated with PAH and mortality in SSc patients. Future longitudinal studies are recommended to investigate the timing and pathogenic mechanisms of this autoantibody in PAH.
Keywords: Humans
Scleroderma, Systemic
Cohort Studies
Cross-Sectional Studies
Pulmonary Arterial Hypertension
Description: Published online: 14 Apr 2021
Rights: © 2021 Scandinavian Journal of Rheumatology Foundation
DOI: 10.1080/03009742.2021.1887927
Grant ID:
Published version:
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.